Wegovy 1.7mg Flextouch Pre Filled Pen

Wegovy 1.7mg Flextouch Pre Filled Pen contains Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist used for chronic weight management and to reduce the risk of major adverse cardiovascular events.

Benefits

This medication works by mimicking a natural hormone to reduce appetite and slow gastric emptying, which helps in achieving significant weight loss. It can also lead to improvements in cardiovascular risk factors such as blood pressure and cholesterol levels. Additionally, it is indicated for managing metabolic dysfunction-associated steatohepatitis (MASH).

Uses and Indications

• Weight management, including weight loss and maintenance, in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes mellitus, dyslipidemia, obstructive sleep apnea, or cardiovascular disease).
• Reduction of the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight.
• Treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults.
• Weight management in adolescents aged 12 years and above with obesity.

The Wegovy 1.7mg Flextouch Pre Filled Pen contains:

• Active ingredient: Semaglutide 1.7mg.
• Other ingredients: Disodium phosphate dihydrate, propylene glycol, phenol, sodium hydroxide/hydrochloric acid (for pH adjustment), and water for injection.

Dosage and Administration

1. Wegovy 1.7mg Flextouch Pre Filled Pen is administered once weekly as a subcutaneous injection.
2. Inject into the abdomen, thigh, or upper arm. Rotate injection sites with each dose. Do not inject into a vein or muscle.
3. The starting dose is typically 0.25 mg once weekly, gradually increasing over 16 weeks to a maintenance dose, which can be 1.7 mg or 2.4 mg, as prescribed by your doctor.
4. The day of weekly administration can be changed if necessary, provided at least 3 days have passed since the last dose.

Storage and Disposal

• Store unopened Wegovy 1.7mg Flextouch Pre Filled Pen in a refrigerator (2°C to 8°C / 36°F to 46°F) in the original carton to protect from light. Do not freeze.
• Once in use, the pen can be kept for up to 6 weeks at a temperature below 30°C (86°F) or in a refrigerator (2°C to 8°C). Keep the pen cap on to protect from light.
• Dispose of the used pen in an FDA-cleared sharps disposal container immediately after use.

Precautions and Safety

• Wegovy may cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in rodents; the human relevance is unknown. Do not use if you or your family have a history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Monitor for symptoms of thyroid tumors such as a lump or swelling in the neck, hoarseness, or trouble swallowing.
• There is a risk of pancreatitis (inflammation of the pancreas) and gallbladder problems. Seek medical attention for severe abdominal pain.
• Hypoglycemia (low blood sugar) can occur, especially if used with insulin or sulfonylureas.
• Dehydration leading to kidney problems, serious allergic reactions, increased heart rate, and changes in vision (diabetic retinopathy) in type 2 diabetic patients are possible risks.
• Monitor for new or worsening depression, suicidal thoughts, or unusual changes in mood or behavior.

Side Effects and Risks

• Common side effects include nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia (indigestion), dizziness, abdominal distension (bloating), and belching.
• Low blood sugar is a common side effect in people with type 2 diabetes.

Disclaimer

Use this medicine only under the prescription and guidance of a qualified doctor or pharmacist.